Novartis Ag

Eric Billy

Juerg Hunziker

Francois Jean-Charles Natt

Christian Rene Schnell

Frank Peter Stegmeier

William Raj Sellers

Francesco Hofmann

Gregory Hoffman

Tobias Schmelzle

Michael Ray Schlabach, Jr

Antoine De Weck

Javad Golji

Audrey Kauffmann

Konstantinos John Mavrakis

Earl Robert McDonald, Iii

François Jean-Charles Natt

The disclosure provides novel personalized therapies, kits, transmittable forms of information and methods for use in treating patients having cancer, wherein the cancer is amenable to therapeutic treatment with an inhibitor, e.g., an inhibitor of any of the targets disclosed herein. Kits, methods of screening for candidate inhibitors, and associated methods of treatment are also provided.

Compositions and methods to treat cancer

Short interfering ribonucleic acid (siRNA) for oral administration, said siRNA comprising two separate RNA strands that are complementary to each other over at least 15 nucleotides, wherein each strand is 49 nucleotides or less, and wherein at least one of which strands contains at least one chemical modification.

Short interfering ribonucleic acid (siRNA) for oral administration

Short interfering ribonucleic acid (siRNA) with improved pharmacological properties

Growing community of inventors

Basel, Switzerland

Eric Billy